AzTrials
AzTrials

PulpitisSMART-PULPNCT07450235

Measurement of Pro-resolving Inflammation Biomarkers in Saliva, Gingival Fluid, and Dental Pulp in Patients With Symptomatic Pulpitis and Healthy Controls

An observational study of Pulpitis and Healthy, run by Université de Nantes at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This observational study aims to better understand inflammation inside the dental pulp (the inner tissue of the tooth) in patients with symptomatic pulpitis compared with healthy individuals. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pulpitis, Healthy
How many people
50 participants
Where
1 siteFrance
Study dates
1 Mar 2026to Dec 2028
How long will I take part?
3 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients consulting at the dental clinic of Nantes University Hospital.

Who may be able to join

  • Age ≥ 18 years, male or female.
  • Patient consulting for symptomatic pulpitis (confirmed clinical and radiographic diagnosis) or for wisdom tooth extraction (healthy subject).
  • Patient able to understand the research and having signed a written consent form.
  • Permanent teeth only.

Who cannot join

  • Refusal to participate.
  • Pregnancy or breastfeeding.
  • Antibiotic or anti-inflammatory treatment in the week prior to sampling.
  • Clinically diagnosed inflammatory gingival or periodontal disease (gingivitis or periodontitis)
  • Chronic systemic inflammatory disease (e.g., uncontrolled diabetes, autoimmune diseases).
  • Patients under guardianship, conservatorship, or legal protection

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Alexis Mr Gaudin, Professor contact

+33240412913

Alexis.Gaudin@univ-nantes.fr

France1 site
  • Nantes University Hospital Dental Clinic

    Nantes, Loire-Atlantique, 44 000

    Juliette Mme Jamoneau, PhD Student, 0240412982, juliette.jamoneau@etu.univ-nantes.fr

Other trials in France

About this study

Official title: Strategic Inflammation Modulation and Advanced Regenerative Therapy of Dental PULP

This observational study aims to better understand inflammation inside the dental pulp (the inner tissue of the tooth) in patients with symptomatic pulpitis compared with healthy individuals.

Researchers will measure inflammation-related biomarkers in saliva, gingival fluid, and dental pulp samples to determine whether these substances reflect the level of inflammation.

The study also evaluates whether saliva and oral fluids could be used as simple, non-invasive tools to detect and monitor pulp inflammation.

We hypothesize that patients with pulpitis will show different biomarker levels compared with healthy controls.

Conditions
Pulpitis, Healthy
Medical subject headings
Pulpitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07450235
Study groupRoleWhat they receive
Healthy patientsHealthy group (healthy patients undergoing wisdom tooth extraction for orthodontic or prophylactic reasons)
Patients with pulpitisSick group (patients with symptomatic pulpitis requiring endodontic treatment)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measurement Compare LXA4 and RvE1 levels in saliva, gingival crevicular fluid, and dental pulp in patients with dental pulpitis and healthy subjects.

    Average concentration of LXA4 and RvE1 (expressed in pg/mL or ng/mL) measured by mass spectrometry in each type of biological sample, compared between the pulpitis group and the healthy group.

    Measured: Day 0 (initial visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2026
  2. Study start1 Mar 2026 (estimated)
  3. Primary completionJul 2028 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07450235
Sponsor's protocol ID
GNEDS-AVIS-25-116-12-030
Acronym
SMART-PULP
Status last verified
Feb 2026
First submitted
26 Feb 2026
Last updated
4 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Pseudonymized participant data (including age, gender, clinical dental characteristics, LXA4 and RvE1 concentrations in saliva/crevicular fluid/pulp, mass spectrometry results), collected during the initial visit to the dental clinic at Nantes University Hospital.

Publications

  • Khoshbin E, Salehi R, Behroozi R, Sadr S, Zamani A, Farhadian M, Karkehabadi H. The effect of low-dose aspirin on aspirin triggered lipoxin, interleukin 1 beta, and prostaglandin E2 levels in periapical fluid: a double-blind randomized clinical trial. BMC Oral Health. 2023 Jul 31;23(1):530. doi: 10.1186/s12903-023-03243-0.

    PubMed 37525211

Questions about this trial

What is this clinical trial studying?

An observational study of Pulpitis and Healthy, run by Université de Nantes at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Alexis Mr Gaudin, Professor (+33240412913, Alexis.Gaudin@univ-nantes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measurement Compare LXA4 and RvE1 levels in saliva, gingival crevicular fluid, and dental pulp in patients with dental pulpitis and healthy subjects. (time frame: Day 0 (initial visit)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07450235, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in